


CLAIMS

1. (Cancelled)
2. (Currently amended) A compound of formula I



wherein

R₁ is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl-C₁₋₆-alkyl; and
R₂ is hydrogen or C₁₋₆-alkyl;
in free, hydrate or salt form.

3. (Currently amended) A compound according to Claim 4 2 which that is selected from 3-(4-(2-ethylphenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-benzyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-2-yl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-1-yl)-2-carboxamido-indole)-alanine, 3-(4-(2-butoxy-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-propyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-isopropyl-phenyl)-2-carboxamido-indole)-alanine, and 3-(4-(2,4-dichloro-phenyl)-2-carboxamido-indole)-alanine, or a and pharmaceutically-acceptable salts therefor thereof.

4. (Currently amended) A compound according to Claim 3 2 which that is 3-(4-(2-ethylphenyl)-2-carboxamido-indole)-D-alanine, in free form or in a pharmaceutically-acceptable salt form.


5. (Cancelled)

6. (Currently amended) A pharmaceutical composition comprising a compound as defined according to Claim 4 2, in free form or in pharmaceutically-acceptable salt form, in association with a pharmaceutically-acceptable diluent or carrier therefor.

7. (Cancelled)

8. (Currently amended) A pharmaceutical combination comprising a compound according to Claim 4 2 in free form or in a pharmaceutically-acceptable salt form and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory and chemotherapeutic drug agents.

9. (Withdrawn by the Examiner) A process for the production of the compound according to claim 2, which process comprises deprotecting a compound of



formula II:

wherein R₁ and R₂ are as defined in claim 2,

R₆ is C₁₋₆alkyl or benzyl,

R₇ is an amino protecting group,

and optionally converting the compound of formula I obtained in free form to a salt form or vice versa.

10. (Withdrawn by the Examiner) A method for treating or preventing disorders or diseases mediated by lymphocytes, acute or chronic transplant rejection, T-

cell mediated inflammatory or autoimmune diseases, diabetes, allergic diseases, myocarditis, hepatitis, ischemia/reperfusion injury, renal failure, hemorrhage shock, traumatic shock, cancer or infectious diseases, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.